ACADL

Across TCGA pan-cancer cohorts, ACADL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACADL data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACADL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACADL expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where ACADL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.577	0.886	.006	12	view →
LSCC	DFS	Quartile	All	0.816	0.999	.018	8	view →
GBM	DFS	Tertile	All	0.248	0.444	.003	6	view →
HNSC	OS	Tertile	IV	1.000	0.628	.044	2	view →
LUAD	DFS	Quartile	All	0.911	0.985	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACADL–CCRCC (DFS)

Open the CCRCC breakdown →